Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

# Complete Title of Study
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension

# Study Acronym (The trial's abbreviation if there is one)
ACCOMPLISH

# Principal Investigator, Co-investigators, and Collaborating Institutions
Study Chair: Novartis Pharmaceuticals

# Overview of Trial
The goal of the ACCOMPLISH trial was to compare the effectiveness of two combination drugs (amlodipine/benazepril and benazepril/HCTZ) on reducing heart disease and death in 11,464 high risk hypertensive patients.

# Disease State(s) Studied (e.g. acute MI, breast cancer, etc.)
- Hypertension

# Study Phase (e.g. Phase I,II,III,IV) Study Phases are defined here
Phase III

# Study Design (e.g. multicenter, randomized, double blind, placebo controlled)
Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

# Study Arms and How They Were Treated (Intervention) (Explanation here)
Drug: Benazepril/amlodipine

# Primary Pre-Specified Endpoint
- Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,
- stroke, hospitalization for chest pain or heart failure, or
- procedure to open a blockage in an arterial blood vessel

# Secondary Endpoints
- Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,
- stroke, or hospitalization for heart failure or or
- procedure to open a blockage in an arterial blood vessel
- Risk of developing diabetes
- Progression of kidney disease

# Inclusion Criteria
- At least 55 years of age.
- Have elevated blood pressure and at least one other cardiovascular disease or diabetes or evidence of damage to the kidneys, brain, blood vessels or heart as defined in the protocol

# Exclusion Criteria
- Allergy to any of the drugs administered in this trial. Selected laboratory tests
- Other protocol-defined exclusion criteria may apply.

# Outcome: Primary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Secondary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Exploratory endpoints (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)
None reported

# Outcome: Safety endpoints (Report both relative risk and absolute risk as well as number needed to harm if available)
None reported

# Conclusions of the Investigators (Quote the investigators conclusions here)
None reported

# Commentary, Discussion and Limitations of the Trial (Anyone can add comments)
None reported

# Slides
None reported

# Video Commentary
None reported

# References (How to insert a reference)
Jamerson K, Weber MA, Bakris GL;  et al. (2008). "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients". N. Engl. J. Med. 359 (23): 241728. doi:10.1056/NEJMoa0806182. PMID 19052124. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link) .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"\"""\"""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{display:none;font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}

# External sites for further information (How to insert links)
None reported

# Detailed information about the trial

# Ages
55 years and older

# Gender (Indicate whether men, women or both were enrolled)
Both

# Accepts Healthy Volunteers (Answer yes or no)
None reported

# Enrollment Period (Study start and end date)
Study start date: October 2003

# Recruitment Status (explanation)
Completed

# Enrollment (Total number of patients enrolled)

# Study Sponsor (e.g. Investigator initiated or company name)
Novartis Pharmaceuticals

# Source of Data (Where is this data on this page coming from: publication, principal investigator, or co-investigator)
Novartis
The content of the clinical trial wiki consists of fields that have been suggested by the World Health Organization and wwww.clinicaltrials.gov.